Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia
Crossref DOI link: https://doi.org/10.1007/s00432-017-2385-7
Published Online: 2017-03-08
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hoffmann, Verena S.
Hasford, Joerg
Deininger, Michael
Cortes, Jorge
Baccarani, Michele
Hehlmann, RĂ¼diger
License valid from 2017-03-08